Anne M Fitzpatrick1, Abby D Mutic2, Ahmad F Mohammad3, Susan T Stephenson3, Jocelyn R Grunwell4. 1. Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga; Children's Healthcare of Atlanta, Atlanta, Ga. Electronic address: anne.fitzpatrick@emory.edu. 2. Emory University Nell Hodgson Woodruff School of Nursing, Atlanta, Ga. 3. Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. 4. Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga; Children's Healthcare of Atlanta, Atlanta, Ga.
Abstract
BACKGROUND: Obesity complicates the clinical manifestations of asthma in children. However, few studies have examined longitudinal outcomes or markers of systemic inflammation in obese asthmatic children. OBJECTIVE: We hypothesized that obese children with asthma would have: (1) poorer clinical outcomes over 12 months, (2) decreased responsiveness to systemic corticosteroid administration, (3) greater markers of systemic inflammation, and (4) unique amino acid metabolites associated with oxidative stress. METHODS: Children 6 to 17 years of age (lean, N = 257; overweight, N = 99; obese, N = 138) completed a baseline visit and follow-up visit at 12 months. Outcome measures included asthma control, quality of life, lung function, and exacerbations. A subset received intramuscular triamcinolone and were re-evaluated at 7(+7) days. Leptin, adiponectin, C-reactive protein, total cholesterol, interleukin (IL)-1β, IL-6, IL-17, interferon gamma, tumor necrosis factor alpha, monocyte-chemoattractant protein-1, and amino acid metabolites were also quantified in plasma as potential biomarkers of outcomes in obese children. RESULTS: Obesity was associated with more symptoms, poorer quality life, and more exacerbations that persisted over 1 year despite greater medication requirements. Obese children also had minimal clinical improvement in asthma control and lung function after intramuscular triamcinolone. Leptin, C-reactive protein, and amino acid metabolites associated with glutathione synthesis and oxidative stress differed in obese children. Within the obese group, lower concentrations of arginine-related metabolites also distinguished uncontrolled from controlled asthma at 12 months. CONCLUSION: Obesity is associated with poorer asthma outcomes and unique systemic inflammatory features that may not be adequately modified with conventional asthma therapies. Novel approaches may be needed given increased symptoms and unique inflammation and oxidative stress in obese children with asthma.
BACKGROUND: Obesity complicates the clinical manifestations of asthma in children. However, few studies have examined longitudinal outcomes or markers of systemic inflammation in obese asthmatic children. OBJECTIVE: We hypothesized that obese children with asthma would have: (1) poorer clinical outcomes over 12 months, (2) decreased responsiveness to systemic corticosteroid administration, (3) greater markers of systemic inflammation, and (4) unique amino acid metabolites associated with oxidative stress. METHODS: Children 6 to 17 years of age (lean, N = 257; overweight, N = 99; obese, N = 138) completed a baseline visit and follow-up visit at 12 months. Outcome measures included asthma control, quality of life, lung function, and exacerbations. A subset received intramuscular triamcinolone and were re-evaluated at 7(+7) days. Leptin, adiponectin, C-reactive protein, total cholesterol, interleukin (IL)-1β, IL-6, IL-17, interferon gamma, tumor necrosis factor alpha, monocyte-chemoattractant protein-1, and amino acid metabolites were also quantified in plasma as potential biomarkers of outcomes in obese children. RESULTS: Obesity was associated with more symptoms, poorer quality life, and more exacerbations that persisted over 1 year despite greater medication requirements. Obese children also had minimal clinical improvement in asthma control and lung function after intramuscular triamcinolone. Leptin, C-reactive protein, and amino acid metabolites associated with glutathione synthesis and oxidative stress differed in obese children. Within the obese group, lower concentrations of arginine-related metabolites also distinguished uncontrolled from controlled asthma at 12 months. CONCLUSION: Obesity is associated with poorer asthma outcomes and unique systemic inflammatory features that may not be adequately modified with conventional asthma therapies. Novel approaches may be needed given increased symptoms and unique inflammation and oxidative stress in obese children with asthma.
Authors: Lisa G Wood; Qian Li; Hayley A Scott; Sandra Rutting; Bronwyn S Berthon; Peter G Gibson; Philip M Hansbro; Evan Williams; Jay Horvat; Jodie L Simpson; Paul Young; Brian G Oliver; Katherine J Baines Journal: J Allergy Clin Immunol Date: 2018-05-30 Impact factor: 10.793
Authors: John G Elliot; Graham M Donovan; Kimberley C W Wang; Francis H Y Green; Alan L James; Peter B Noble Journal: Eur Respir J Date: 2019-12-12 Impact factor: 16.671
Authors: Erick Forno; Rachel Lescher; Robert Strunk; Scott Weiss; Anne Fuhlbrigge; Juan C Celedón Journal: J Allergy Clin Immunol Date: 2011-03 Impact factor: 10.793
Authors: Caren Ishikawa; Marco Antonio Barbieri; Heloisa Bettiol; Gabriel Bazo; Alexandre A Ferraro; Elcio Oliveira Vianna Journal: BMC Pulm Med Date: 2021-05-25 Impact factor: 3.317
Authors: Shafqat Ahmad; Olga V Demler; Qi Sun; M Vinayaga Moorthy; Chunying Li; I-Min Lee; Paul M Ridker; JoAnn E Manson; Frank B Hu; Tove Fall; Daniel I Chasman; Susan Cheng; Aruna Pradhan; Samia Mora Journal: JAMA Netw Open Date: 2020-11-02